China Has Approved the World’s First Invasive Brain-Computer Chip—Here’s What’s Next
Chinese startup Neuracle’s NEO invasive brain‑computer interface received the world’s first regulatory approval for commercial use, allowing patients with spinal‑cord paralysis to regain hand function. The coin‑size device, placed on the dura mater, enabled patient Dong Hui to write and grasp objects within days of surgery. Approval follows 36 clinical trials and an expedited pathway under China’s five‑year plan that lists BCI as a priority industry. The chip now enters China’s health‑insurance system, signaling a shift from lab prototypes to scalable medical products.
Amid Ebola, Hantavirus Outbreaks, Democrats Decry Trump’s Health Cuts
The Trump administration’s sweeping cuts to federal health agencies have become a flash point as a hantavirus outbreak aboard the MV Hondius and a growing Ebola epidemic in Uganda and the Democratic Republic of Congo draw public attention. Democrats argue...
2026 Orphan Drugs Report: A Safe(r) Passage Amid Stormy Waters?
Orphan drug sales are on a steady climb, projected to represent over 21% of global prescription drug revenue by 2032—about $400 billion of an estimated $2 trillion market. The top eight orphan products will each exceed $6 billion in sales, with Darzalex leading...
Beyond the Clinical Note: Why the Next Decade of EHR Success Is Financial
Electronic health record (EHR) vendors are shifting from digitizing clinical notes to becoming the financial operating system for medical practices. ModMed, discussed on Adyen’s Embedded Finance podcast, has integrated payments, reduced accounts receivable, and plans to add accounts‑payable automation, business...
SKIA Secures FDA 510(k) Clearance for AR Surgical Platform
South Korean med‑tech firm SKIA has secured FDA 510(k) clearance for its AR surgical guidance platform, SKIA HEAD. The tablet‑based system, paired with Structure’s medical‑grade sensors, projects three‑dimensional reconstructions onto patients in real time. Clearance clears the path for a...
Eli Lilly Highlights P-III (LIBRETTO-432) Trial Data on Retevmo for Early-Stage RET Fusion–Positive NSCLC at ASCO 2026
Eli Lilly presented data from its phase III LIBRETTO‑432 trial of selpercatinib (Retevmo) as adjuvant therapy in early‑stage RET‑fusion positive NSCLC. In 151 patients, the drug reduced the risk of disease recurrence or death by 83% versus placebo, with 24‑month...
Effectiveness of a Multisectoral Community-Based Intervention for Psychosis in West and Southeast Africa: Protocol of the SUCCEED Africa Randomised Controlled...
The SUCCEED Africa project is conducting two parallel, open‑label randomized controlled trials in Nigeria and Zimbabwe to test a multisectoral, community‑based intervention for adults living with psychosis. Over a 12‑month period, participants receive formal peer support, case management that mobilises...
Royal Cornwall Hospitals to Delay EPR Go-Live as “Necessary and Appropriate Assurance Action”
Royal Cornwall Hospitals NHS Trust has postponed its eCare electronic patient record (EPR) go-live originally slated for June, citing insufficient assurance that the system could safely support patient care. A 60‑day readiness review and a NHSE 90‑day assessment rated the...
Lynk Pharmaceuticals Receives NMPA Approval for Phase II Trial of LNK01004 Ointment
Lynk Pharmaceuticals received approval from China’s National Medical Products Administration to begin Phase II trials of its internally developed LNK01004 ointment for vitiligo and chronic hand eczema. The ointment is a skin‑restricted pan‑JAK inhibitor designed to minimize systemic exposure while targeting...
Akeso Presents the P-III (HARMONi-6) Trial Data on Ivonescimab + CT in 1L Squamous NSCLC at ASCO 2026
Akeso’s global Phase III HARMONi‑6 trial compared ivodescimab plus chemotherapy with Tevimbra plus chemotherapy in 532 patients with first‑line squamous non‑small cell lung cancer. The study met its primary overall‑survival endpoint, showing a 34% reduction in death risk (median OS 27.9 months...
Budget 2026: New Zealand Funds Digital Health Upgrades, Cybersec
The New Zealand government’s Budget 2026 earmarks roughly NZ$450 million ($270 million) for health‑sector digital upgrades and cybersecurity. NZ$153.6 million ($91.7 million) will fund a 24/7 national cyber‑monitoring programme under Te Whatu Ora, while NZ$300 million ($179 million) supports the first three years of the Health Digital Investment Plan, replacing...
Privacy Watchdog Faults Operator, Health NZ over Manage My Health Hack
New Zealand’s Privacy Commissioner concluded that Te Whatu Ora Health New Zealand and Manage My Health Ltd breached Rule 5 of the Health Information Privacy Code after a cyberattack compromised the My Health Documents portal. Approximately 99,416 patients—mostly in Northland—had personal and...
Structural Convergence in Behavioural Healthcare: Analysis of the Universal Health Services Acquisition of Talkspace
Universal Health Services (UHS) announced a definitive agreement to acquire Talkspace for $5.25 per share, valuing the digital behavioural‑health platform at roughly $835 million. Talkspace’s FY 2025 revenue rose to $228.9 million, delivering its first GAAP profit, while the deal will be funded...
Scientists Unveil 3D Color Imaging Technique for Real-Time Human Scans
Researchers at Caltech and USC unveiled RUS-PAT, a hybrid imaging system that fuses rotational ultrasound tomography with photoacoustic tomography to generate high‑resolution 3D images of tissue structure and blood‑vessel function in real time. The technique overcomes the two‑dimensional limitation of...
Desperate to Fight Ebola Outbreak, Congo Weighs Using Longshot Vaccine Options
The Democratic Republic of the Congo is battling a fast‑spreading Bundibugyo Ebola outbreak that has produced 291 confirmed cases and 43 deaths in two weeks. With no licensed vaccine for the rare BDBV strain, health officials are debating the emergency...
Wockhardt Marks Research Milestone with USFDA Approval for Novel Antibiotic Zaynich
Wockhardt has secured US FDA approval for Zaynich, an intravenous antibiotic combining cefepime and zidebactam, to treat complicated urinary tract infections in adults. The drug earned Qualified Infectious Disease Product and Fast Track designations and follows recent clearance by India’s...
PSMA PET Detects High-Risk Prostate Cancer Bone Metastases
A retrospective study of 36 prostate‑cancer patients at UCSF and UCLA found that PSMA PET imaging detects bone metastases missed by conventional bone scans and CT. Over 80% of these patients had normal standard imaging, yet even a single PSMA‑positive...
New Imaging Method Distinguishes Inflammation From Lung Fibrosis
A new SPECT/CT imaging technique using the tracer 99mTc‑maraciclatide can reliably differentiate inflammation from fibrosis in patients with interstitial lung disease (ILD). In a pilot study of 15 participants—including idiopathic pulmonary fibrosis, fibrotic hypersensitivity pneumonitis, and healthy controls—the method showed...
Chairside Dental AM: From All Sides
Chairside 3D printing is now employed in roughly 15% of U.S. dental practices, outpacing chairside milling but still far behind intra‑oral scanners and lab‑based additive manufacturing, which exceed 60% adoption. The technology is used for models, splints, night guards, surgical...
OBBBA and Medicaid: What Urban Safety Net Hospitals Need to Know Now
The One Big Beautiful Bill Act (OBBBA), enacted July 4 2025, introduces stricter Medicaid eligibility rules, including work requirements and six‑month redeterminations, that will take effect between late 2026 and early 2027. Expanded cost‑sharing and tighter state financing limits are expected to shrink Medicaid enrollment and reduce reimbursements...
India Achieves AI Breakthrough in Cancer Care with Mask-Free, Simulationless Radiotherapy
Sir HN Reliance Foundation Hospital in India successfully treated a head‑and‑neck cancer patient using a mask‑free, simulation‑less radiotherapy protocol that combines Surface Guided Radiotherapy (SGRT) and adaptive radiotherapy. The approach eliminated the need for immobilisation masks and simulation CT scans,...
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) From Phase I/II Study in Heavily Pretreated mCRPC...
MHB088C, a B7‑H3‑targeted antibody‑drug conjugate from Minghui Pharmaceutical, presented updated Phase I/II data in heavily pretreated metastatic castration‑resistant prostate cancer (mCRPC) at the 2026 ASCO Annual Meeting. Among 59 enrolled patients, median radiographic progression‑free survival was not reached, with a...
When a GPP Flare Needs Urgent Care
Generalized pustular psoriasis (GPP) can erupt suddenly, producing red plaques, pustules, fever and systemic inflammation that may damage kidneys, liver or lungs. Dermatologist David Xiong warns that severe flares constitute a medical emergency, especially when accompanied by shortness of breath,...
Virtual Care in America: The Populus Report
The Populus Report defines virtual care as any digital environment where patients and providers exchange clinical attention, positioning telehealth as a subset. Survey data from over 1,250 patients, providers, and pharma marketers shows virtual care accelerates access, with 76% of...
‘Death By 1,000 Cuts’: How Home-Based Care Leaders Navigate Reimbursement Pressure
Home‑based care providers are feeling the squeeze from a cascade of reimbursement cuts across Medicare, Medicare Advantage, Medicaid and VA programs. CMS has lowered the Medicare home‑health base rate for several years, while Medicare Advantage often pays below cost, creating...
Daily Pill Doubles Survival Time for Pancreatic Cancer Patients
A phase III trial of the oral KRAS inhibitor daraxonrasib showed median overall survival of 13.2 months for advanced pancreatic cancer patients, roughly double the 6.6 months achieved with standard chemotherapy. The study enrolled 500 participants across North America, Europe...
Memphasys Signs Distribution Deal for Felix Fertility Device Into IVF Clinics Throughout Vietnam
Memphasys secured a $530,000 two‑year commercialization agreement with TMSC Vietnam to distribute its Felix electrophoresis‑based sperm‑separation device across IVF clinics in Vietnam. The contract provides $205,000 in the first year and $325,000 in the second, with an initial $50,000 order...
Greenwich Lifesciences Inc (GLSI) Q4 2025 Earnings Call Transcript
Geron Corp. reported full‑year 2025 net revenue of $184 million for its Rytelo hematology drug and projected 2026 revenue between $220 million and $240 million, driven by sequential demand growth and a focus on the estimated 8,000 eligible second‑line lower‑risk MDS patients in...
Passive Heart-Rate Monitoring During Smartphone Use in Everyday Life
Researchers unveiled a smartphone‑based deep‑learning system, PHRM, that passively measures heart rate and daily resting heart rate during routine phone use. The platform was validated on over 162,000 videos from diverse participants, meeting industry accuracy standards with mean absolute percentage...
First Comprehensive Look at Breast Cancer in Native American Women Reveals Key Genetic Differences
Researchers at the University of Notre Dame published the first detailed genetic analysis of breast cancer in Native American women, comparing 17 tumor samples with nearly 700 white‑patient cases from The Cancer Genome Atlas. The study, appearing in npj Precision...
Dual PET Imaging Detects Tumor Progression and Heart Inflammation During Cancer Treatment
Researchers unveiled a dual PET imaging method that simultaneously visualizes tumor growth and cardiac inflammation using a CCR2‑targeted radiotracer, 64Cu‑DOTA‑ECL1i. In mouse models, checkpoint inhibitor therapy slowed tumors but heightened cardiac CCR2 signals, while adding the JAK1 inhibitor itacitinib improved...
Can Wegovy Move the Needle on NZ’s Obesity Crisis, or Simply Treat Its Symptoms?
New Zealand’s drug‑funding agency Pharmac has placed semaglutide‑based Wegovy on its future funding list, targeting people with severe obesity or weight‑related health conditions. Currently the drug costs about NZ$400 a month (≈US$240), putting it out of reach for many, especially...
Early Interventions Can Help Women Achieve Optimal Weight Gain During Pregnancy, Review Suggests
A systematic review in BMJ Global Health finds that early nutrition, education and physical‑activity interventions in low‑ and middle‑income countries help pregnant women achieve optimal gestational weight gain, reducing both under‑ and over‑gain. Physical activity programs were most effective at...
Lesser-Known Cannabis Compounds Show Promise for Treating Alcohol Addiction in Rats
A pre‑clinical study on male Wistar rats found that daily injections of three phytocannabinoids—cannabinol (CBN), tetrahydrocannabivarin (THCV) and cannabidiol (CBD)—reduced voluntary alcohol consumption. CBN and THCV produced the strongest declines, with CBN’s effect persisting three days after treatment, while CBD...
Mich. EMS Students Put Rescue Skills to the Test at Beach Training Day
Careerline Tech Center’s EMS program held its annual beach‑rescue capstone on May 6 at Kirk Park, where senior students tackled simulated emergencies such as cardiac arrest, grill explosions and allergic reactions. Guided by Grand Haven Township Fire Department, Life EMS responders...
Long-Term Leukemia Trial Reveals MRD-Triggered Treatment May Slow or Prevent Relapse
The RELAZA2 trial has released its long‑term data, confirming that azacitidine administered at the first sign of measurable residual disease (MRD) can significantly delay relapse in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). As the world’s first prospective MRD‑triggered...
Medical Education Is at a Crossroads. AI Isn’t the Problem — It’s the Mirror
Medical education faces a pivotal shift as AI tools become ubiquitous in clinical training. While large language models can now pass the USMLE, their performance drops in real‑world, context‑rich encounters, exposing a gap between exam‑centric teaching and actual practice. The...
Pocket-Sized Device Rivals Bulky Lab Machinery in Disease and Environmental Testing
Micronix Co., Ltd. has launched POTA, a pocket‑sized spectrophotometer that matches the performance of traditional lab‑grade instruments. The device, developed at Kumamoto University, uses a novel tapered spatial filter to suppress stray light, allowing a simple LED and color sensor...
Experimental Pill Promises New Hope for Deadly Pancreatic Cancer
Researchers reported that the experimental pill daraxonrasib, which blocks mutated KRAS proteins, nearly doubled median survival for patients with advanced pancreatic cancer to 13.2 months versus 6.7 months on chemotherapy. The drug showed fewer severe side effects and improved quality...
ASCO26: Big Win for Erleada in Perioperative Prostate Cancer
Johnson & Johnson’s Erleada (apalutamide) dramatically improved outcomes when added to radical prostatectomy plus androgen‑deprivation therapy in a 2,109‑patient global trial presented at ASCO. Complete or near‑complete pathological response rose ninefold to 8.9% versus 1% in the control arm. Patients...
STAT+: For Prostate Cancer Patients Set on Surgery, New Hormone Regimen May Improve Outcomes, Study Finds
A phase‑3 PROTEUS trial found that administering two hormone therapies before and after prostatectomy outperformed a single‑hormone regimen in high‑risk, early‑stage patients. The dual approach reduced biochemical recurrence and improved margin‑negative resection rates. Oncologists view the data as a potential...
STAT+: Akeso and Summit’s Ivonescimab Extends Survival in Squamous Cell Lung Cancer
Ivonescimab, a dual‑action antibody co‑developed by Akeso Therapeutics and Summit Therapeutics, cut mortality risk by 34% versus standard therapy in a China‑only trial for squamous non‑small cell lung cancer. The data, unveiled at ASCO and published in The Lancet, represent...
When to Retreat, When to Switch in CLL Treatment Decision-Making: Adam Kittai, MD
Dr. Adam Kittai, director of NYU Langone’s CLL program, discussed the evolving treatment sequencing for chronic lymphocytic leukemia in an AJMC interview. He highlighted the challenges of retreating with venetoclax after a drug‑free interval and the emerging role of triplet...
Precision in Practice: The Strategic Role of Contract Design & Manufacturing in Medical Device Innovation
Partnering with specialized contract design and manufacturing firms like Access Optics lets medical‑device companies boost operational efficiency, scale production quickly, and tap advanced micro‑optical expertise without heavy internal investment. The white paper highlights how outsourcing critical processes—especially glass‑to‑metal hermetic sealing...
This Daily Movement Metric Could Spot Parkinson’s Years Earlier
A UK Biobank study of 95,000 adults found that lower daily step counts precede Parkinson’s diagnoses by up to two years. Participants walking fewer than 6,276 steps per day faced a markedly higher risk, while those exceeding 12,369 steps enjoyed...
NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO
NeuExcell Therapeutics announced that its first‑in‑human gene therapy NXL‑004 for recurrent malignant glioma earned a Rapid Oral presentation slot at ASCO 2026. The AAV‑NeuroD1 platform was tested in eleven patients, showing a favorable safety profile with no drug‑related serious adverse...
A Prodrug Approach for Activity‐Based Chemical Modulation Toward Multiple Pathological Targets in Alzheimer's Disease
Researchers have developed a pathology‑responsive prodrug platform that exploits elevated hydrogen peroxide in Alzheimer’s disease to release redox‑active aminophenols. The lead compound, BE‑1 remains inert until oxidative deboronation triggers its conversion, enabling simultaneous ROS scavenging and modulation of amyloid‑β aggregation,...
A New Study Suggests Heart Attacks Can Leave A Neurological “Aftershock”
A University of Ottawa study discovered that the metabolic by‑product methylglyoxal (MG) accumulates in the brain shortly after a heart attack, especially in the cortex and brainstem. This buildup triggers neuroinflammation, weakens the blood‑brain barrier, and may underlie post‑myocardial infarction...
HIV in South Africa: Why Rolling Out a Groundbreaking New Shot Will Miss a Critical Group of Men
The U.S. shipped the first batch of lenacapavir, a long‑acting injectable HIV‑prevention shot, to South Africa in early April 2026, with rollout slated for June. Clinical trials show close to 100% efficacy with just two doses per year. The national...
Transforming Pathology at Scale: NYU Langone’s Achievement of a Fully Digital Workflow in One Year to Accelerate Diagnosis, Collaboration, and...
NYU Langone Health completed a hospital‑wide transition to a fully digital pathology workflow in just one year, scanning every glass slide into a centralized image repository. The initiative slashed average diagnostic turnaround from roughly 48 hours to 30 hours and...